De­nali, Take­da scrap PhI Alzheimer's drug due to safe­ty sig­nals, 'rapid­ly evolv­ing' land­scape

As Bio­gen takes a pre­clin­i­cal De­nali com­pound tar­get­ing amy­loid be­ta for­ward in Alzheimer’s, De­nali is shelv­ing an­oth­er Alzheimer’s can­di­date that is part­nered with Take­da and hits a dif­fer­ent tar­get.

Phase I da­ta sug­gest that the drug, known as TAK-920 or DNL919, has a “nar­row ther­a­peu­tic win­dow” giv­en safe­ty sig­nals, De­nali said. To­geth­er with Take­da, it now plans to go back to the draw­ing board, fo­cus­ing on back­up mol­e­cules still in the pre­clin­i­cal stage, in­clud­ing po­ten­tial com­bi­na­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER